Search
Now showing items 11-20 of 25
Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727).
(AMER ASSOC CANCER RESEARCH, 2023-09-15)
PURPOSE: The TNT trial (NCT00532727) showed no evidence of carboplatin superiority over docetaxel in metastatic triple-negative breast cancer (mTNBC), but carboplatin benefit was observed in the germline BRCA1/2 mutation ...
Systemic Therapy for Hereditary Breast Cancers.
(W B SAUNDERS CO-ELSEVIER INC, 2023-02-01)
Approximately 5% to 10% of all breast cancers are hereditary; many of which are caused by pathogenic variants in genes required for homologous recombination, including BRCA1 and BRCA2. Here we discuss systemic treatment ...
TGF-β1 potentiates Vγ9Vδ2 T cell adoptive immunotherapy of cancer.
(CELL PRESS, 2021-12-21)
Despite its role in cancer surveillance, adoptive immunotherapy using γδ T cells has achieved limited efficacy. To enhance trafficking to bone marrow, circulating Vγ9Vδ2 T cells are expanded in serum-free medium containing ...
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
(NATURE PUBLISHING GROUP, 2017-04-01)
Approximately 1-5% of breast cancers are attributed to inherited mutations in BRCA1 or BRCA2 and are selectively sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. In other cancer types, germline and/or somatic ...
Crosstalk between Innate Lymphoid Cells and Other Immune Cells in the Tumor Microenvironment.
(HINDAWI LTD, 2016-01-01)
Our knowledge and understanding of the tumor microenvironment (TME) have been recently expanded with the recognition of the important role of innate lymphoid cells (ILC). Three different groups of ILC have been described ...
Tandem duplications contribute to not one but two distinct phenotypes.
(NATL ACAD SCIENCES, 2016-09-06)
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.
(NATURE PORTFOLIO, 2022-04-07)
Platinum derivatives are commonly used for the treatment of patients with metastatic triple-negative breast cancer (TNBC). However, resistance often develops, leading to treatment failure. This expansion cohort (part C2) ...
Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.
(ELSEVIER SCIENCE INC, 2017-06-17)
Triple-negative breast cancer is a heterogeneous disease and specific therapies have not been available for a long time. Therefore, conventional chemotherapy is still considered the clinical state of the art. Different ...
Genomic Evolution of Breast Cancer Metastasis and Relapse.
(CELL PRESS, 2017-08-14)
Patterns of genomic evolution between primary and metastatic breast cancer have not been studied in large numbers, despite patients with metastatic breast cancer having dismal survival. We sequenced whole genomes or a panel ...
Visualization of Tumor-Immune Interaction - Target-Specific Imaging of S100A8/A9 Reveals Pre-Metastatic Niche Establishment.
(IVYSPRING INT PUBL, 2017-06-15)
Background Systemic cancer spread is preceded by the establishment of a permissive microenvironment in the target tissue of metastasis - the premetastatic niche. As crucial players in establishment of the pre-metastatic ...